GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature
<b>Background/Objectives:</b> GLP-1 receptor agonists (GLP-1RAs) have revolutionized weight loss and shown anti-inflammatory actions in several experimental models of colitis. There has been a wealth of recent data suggesting that GLP-1RA treatment may modify disease outcomes in inflamma...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/5/1128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <b>Background/Objectives:</b> GLP-1 receptor agonists (GLP-1RAs) have revolutionized weight loss and shown anti-inflammatory actions in several experimental models of colitis. There has been a wealth of recent data suggesting that GLP-1RA treatment may modify disease outcomes in inflammatory bowel disease (IBD). The aim of this systematic review is to determine if GLP-1RAs can act as a sole or adjunctive agent to induce steroid-free clinical remission in IBD patients. <b>Methods:</b> The PubMed/Medline, Cochrane Clinical Trial, and EMBASE databases were interrogated with a pre-defined search strategy and eligibility criteria to examine the evidence regarding GLP-1RAs’ use in IBD and non-IBD immune-mediated inflammatory disease (IMID) patients. <b>Results:</b> While there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis, there is a lack of prospective clinical studies on treating active IBD with GLP-1RAs to specifically induce steroid-free clinical remission. Surrogate data on better IBD composite outcomes have been reported with the use of GLP-1RAs, including a lower risk of surgery, hospitalization, corticosteroid use, and/or the initiation of advance therapies. Data from non-IBD IMID patients are only available for the effect of these agonists on psoriatic plaques, with positive signals. <b>Conclusions:</b> The current evidence for the role of GLP-1RAs as a potential anti-inflammatory therapy in IBD is limited, but provides the impetus for much-needed prospective studies and RCTs that include patients with active IBD. |
|---|---|
| ISSN: | 2227-9059 |